TY - JOUR
TI - Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors
AU - Chatzirallis, A.
AU - Theodossiadis, P.
AU - Droutsas, K.
AU - Koutsandrea, C.
AU - Ladas, I.
AU - Moschos, M.M.
JO - Cutaneous and Ocular Toxicology (formerly Journal of Toxicology - Cutaneous and Ocular Toxicology)
PY - 2020
VL - 39
TODO - 4
SP - 317-322
PB - Taylor and Francis Ltd.
SN - 1556-9527, 1556-9535
TODO - 10.1080/15569527.2020.1802741
TODO - aflibercept;  hemoglobin A1c;  proxymetacaine;  ranibizumab;  aflibercept;  angiogenesis inhibitor;  fusion protein;  ranibizumab;  vasculotropin receptor, adult;  age;  anatomical concepts;  Article;  best corrected visual acuity;  central retinal thickness;  comparative study;  controlled study;  data analysis software;  demography;  diabetic macular edema;  female;  follow up;  human;  major clinical study;  male;  middle aged;  multivariate analysis;  predictive value;  prospective study;  randomized controlled trial;  spectral domain optical coherence tomography;  treatment outcome;  vision;  aged;  diabetic retinopathy;  diagnostic imaging;  drug effect;  intravitreal drug administration;  macular edema;  non insulin dependent diabetes mellitus;  optical coherence tomography;  visual acuity, Aged;  Angiogenesis Inhibitors;  Diabetes Mellitus, Type 2;  Diabetic Retinopathy;  Female;  Humans;  Intravitreal Injections;  Macular Edema;  Male;  Middle Aged;  Multivariate Analysis;  Ranibizumab;  Receptors, Vascular Endothelial Growth Factor;  Recombinant Fusion Proteins;  Tomography, Optical Coherence;  Treatment Outcome;  Visual Acuity
TODO - Purpose: The purpose of this study was to compare the anatomical and functional outcomes of ranibizumab versus aflibercept for the treatment of diabetic macular edema (DME) in a long-term follow-up. Methods: Participants in this prospective study were 112 treatment naïve patients with DME, who received treatment with either intravitreal ranibizumab (n = 54) or aflibercept (n = 58). The demographic data, the best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT) characteristics were evaluated at baseline and at month 1, 2, 3, 6, 12, and 18 post treatment, while factors affecting visual outcome were determined using multivariate analysis. Results: At month 18, the mean BCVA of ranibizumab-treated eyes increased 7.9 letters compared to 6.9 letters for eyes receiving aflibercept, with greater number of injections in ranibizumab group (9.2 ± 2.3 vs. 7.6 ± 2.1 injections in the ranibizumab and aflibercept group respectively, p = 0.0002). The difference in letters between the two groups was not statistically significant, nor the difference in central subfield thickness at month 18. Factors associated with poorer BCVA were found to be increasing age, HbA1c ≥7.5%, increasing central retinal thickness and disrupted ellipsoid zone. Conclusions: Ranibizumab and aflibercept presented similar anatomical and functional outcomes in 18-month follow-up in patients with DME. It is important to determine factors, affecting VA, so as to provide individualized treatment. © 2020 Informa UK Limited, trading as Taylor & Francis Group.
ER -